NousCom is a cancer vaccine company developing two different approaches using its highly immunogenic viral vectors. Its ‘off-the-shelf’ cancer vaccine targets subgroups of patients with cancers that have a specific genetic feature (biomarker) called microsatellite instability high (MSI-H), which is associated with a poor prognosis. Its personalised vaccines use a patient’s own neoantigens (novel cancer-related antigens). These programmes have shown highly promising preclinical results and should both enter the clinic in 2018.

Location Basel, Switzerland
CEO Alfredo Nicosia
Partner Genghis Lloyd-Harris